Anti-Monkeypox virus/MPXV A29L Nanobody (A229)

Cat# APR11105

Size : 0.1mg

Brand : Abcepta

Contact local distributor :


Phone : +1 850 650 7790

Anti-Monkeypox virus/MPXV A29L nanobody (A229)

Antibody

 
  •  - Anti-Monkeypox virus/MPXV A29L nanobody (A229) APR11105

    Anti-Monkeypox virus/MPXV A29L Nanobody (A229) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

  •  - Anti-Monkeypox virus/MPXV A29L nanobody (A229) APR11105

    Immobilized Monkeypox Virus A29L, His Tag at 2 ug/mL can bind Anti-Monkeypox virus/MPXV A29L Nanobody (A229), EC50=0.004267 ug/mL.

Anti-Monkeypox virus/MPXV A29L Nanobody (A229) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Product Information

Application
  • Applications Legend:
  • WB=Western Blot
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin-embedded Sections)
  • IHC-F=Immunohistochemistry (Frozen Sections)
  • IF=Immunofluorescence
  • FC=Flow Cytopmetry
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • E=ELISA
  • IP=Immunoprecipitation
  • DB=Dot Blot
  • CHIP=Chromatin Immunoprecipitation
  • FA=Fluorescence Assay
  • IEM=Immuno electron microscopy
  • EIA=Enzyme Immunoassay
Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Clonality Monoclonal
Isotype VHH

Additional Information

Target/Specificity A29L
Endotoxin <0.001 EU/ µg
Conjugation None
Expression system CHO
Format nanobody
Molecular Weight (kDa) 78.42 kDa
Formulation 0.1 mM Glycine, 0.2 Mm Nacl, (tris), pH 6
Storage -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Research Areas
  • Primary Antibodies
  • Antibody Collections
  • Recombinant Antibodies